OKAY
833230
CHANGFU CO.,LTD
871396
Gansu Longshenrongfa Pharmaceutical Industry
300534
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -438.08%-8.65M | 19.24%-1.55M | 111.35%3.02M | -9,480.43%-4.41M | -284.00%-5.7M | 23.93%2.56M | -43.96%-1.92M | -57.10%1.43M | -104.97%-46K | 463.71%3.1M |
Net income from continuing operations | -190.87%-19.91M | 34.68%-6.57M | -290.30%-6.38M | -362.93%-3.14M | -186.28%-3.82M | -264.24%-6.84M | -811.44%-10.06M | 313.30%3.35M | -54.29%1.2M | -98.62%-1.33M |
Depreciation and amortization | 0.59%2.39M | 0.50%600K | 0.68%595K | -0.17%594K | 1.36%596K | 11.58%2.37M | 5.73%597K | 10.80%591K | 14.23%595K | 16.19%588K |
Deferred tax | 979.58%6.13M | --0 | 7,407.95%6.61M | -504.41%-275K | -170.27%-200K | 440.95%568K | 233.81%486K | 210.61%88K | 74.51%68K | ---74K |
Other non cash items | -712.50%-3.58M | 805.96%1.07M | -3,176.69%-5.02M | 36.76%186K | -57.34%186K | -50.84%584K | -212.43%-151K | 0.68%163K | -8.61%136K | -41.32%436K |
Change In working capital | -12.69%4.15M | -69.84%2.03M | 329.47%7.01M | 16.33%-1.93M | -187.32%-2.96M | 187.90%4.75M | 282.68%6.72M | -264.92%-3.05M | -6.94%-2.3M | 337.51%3.39M |
-Change in receivables | 380.40%31.62M | -95.73%731K | 152.60%13.18M | 118.07%1.92M | 116.09%15.78M | 39.05%-11.28M | 443.50%17.11M | -284.08%-25.06M | -49.38%-10.63M | 6,011.37%7.3M |
-Change in prepaid assets | -129.85%-60K | -53.93%334K | 1.12%-264K | -173.33%-41K | 63.22%-89K | -34.53%201K | 513.84%725K | -378.32%-267K | -118.33%-15K | -179.49%-242K |
-Change in payables and accrued expense | -270.40%-27.41M | 114.13%1.47M | -127.53%-6.11M | -147.33%-3.96M | -364.33%-18.81M | 17.51%16.08M | -596.62%-10.43M | 191.99%22.2M | 70.66%8.37M | -341.63%-4.05M |
-Change in other current liabilities | -38.04%-127K | -100.00%-44K | -95.45%-43K | 16.67%-20K | 16.67%-20K | 6.12%-92K | 2.67%-22K | 15.30%-22K | 25.28%-24K | -38.70%-24K |
-Change in other working capital | 175.90%126K | 29.26%-469K | 163.44%245K | 17,300.00%174K | -56.33%176K | 79.28%-166K | -10.67%-663K | -86.77%93K | -91.34%1K | 143.96%403K |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -438.08%-8.65M | 19.24%-1.55M | 111.35%3.02M | -9,480.43%-4.41M | -284.00%-5.7M | 23.93%2.56M | -43.96%-1.92M | -57.10%1.43M | -104.97%-46K | 463.71%3.1M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 90.45%-17K | 0 | -7K | 88.76%-10K | 0 | 74.13%-178K | 94.04%-41K | 0 | -89K | -48K |
Capital expenditure reported | 90.45%-17K | --0 | ---7K | 88.76%-10K | --0 | 74.13%-178K | 94.04%-41K | --0 | ---89K | ---48K |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 90.45%-17K | --0 | ---7K | 88.76%-10K | --0 | 74.13%-178K | 94.04%-41K | --0 | ---89K | ---48K |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 480.93%4.99M | -168.15%-1.09M | 100.56%9K | 334.93%2.15M | 1,132.11%3.92M | 34.87%-1.31M | 270.08%1.6M | -31.00%-1.61M | -119.76%-916K | -166.12%-380K |
Net issuance payments of debt | -25.89%4.33M | -131.60%-2M | 99.39%-1K | 1,746.34%2.7M | 2,312.20%3.63M | 77.80%5.84M | 3,971.56%6.33M | -104.38%-163K | -19.27%-164K | -19.27%-164K |
Net common stock issuance | --1.65M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Net preferred stock issuance | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Cash dividends paid | --0 | --0 | --0 | ---- | ---- | -88.13%-3.19M | -54.14%-1.2M | -103.81%-1.24M | ---- | ---- |
Proceeds from stock option exercised by employees | 109.06%307K | --0 | --10K | --3K | 2,350.00%294K | ---3.39M | ---3.4M | --0 | --0 | --12K |
Net other financing activities | -123.26%-1.29M | -448.51%-735K | --0 | ---- | ---- | -9.71%-576K | -45,523.73%-134K | 37.10%-214K | --0 | -23.18%-228K |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 480.93%4.99M | -168.15%-1.09M | 100.56%9K | 334.93%2.15M | 1,132.11%3.92M | 34.87%-1.31M | 270.08%1.6M | -31.00%-1.61M | -119.76%-916K | -166.12%-380K |
Net cash flow | ||||||||||
Beginning cash position | 26.41%5.12M | -25.45%4.09M | -81.14%1.07M | -50.38%3.33M | 26.41%5.12M | -13.60%4.05M | -21.81%5.48M | 15.30%5.67M | 52.47%6.72M | -13.61%4.05M |
Current changes in cash | -443.41%-3.67M | -621.86%-2.64M | 1,722.58%3.02M | -115.51%-2.27M | -166.69%-1.78M | 267.82%1.07M | 87.65%-366K | -108.88%-186K | -306.48%-1.05M | 1,062.43%2.67M |
End cash Position | -71.76%1.45M | -71.76%1.45M | -25.45%4.09M | -81.14%1.07M | -50.38%3.33M | 26.41%5.12M | 26.41%5.12M | -21.81%5.48M | 15.30%5.67M | 52.47%6.72M |
Free cash flow | -464.08%-8.67M | 20.93%-1.55M | 110.86%3.01M | -3,171.85%-4.42M | -286.89%-5.7M | 72.97%2.38M | 2.95%-1.96M | -57.10%1.43M | -114.58%-135K | 458.08%3.05M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |